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 Purpose: The aim of this study is to compare photon and proton therapy by 
estimating late radiation lung damage and cardiac toxicity using Dose volume-
histogram, DVH metrices for both lungs and heart in terms of relative cardiac mortality 
and NTCP values for the heart and lungs respectively. The comparison has also been 
made based on the value of mean and maximum doses received by organs at risk 
(OARs). 
Methods: Dose Volume histogram extraction has been made for 6 medulloblastoma, 
3 neuroblastoma, 2 Ewing sarcoma and one rhabdomyosarcoma paediatric patients 
who were treated with proton therapy and re-planed in VMAT retrospectively in order 
to compare proton and photon treatment techniques.   
Results:  Proton treatment techniques reduced the mean dose to the heart and lung 
significantly compared to the photon treatment techniques. Due to the reduced mean 
dose, NTCP values for the lungs and the relative risk of cardiac mortality for the heart 
were reduced significantly by the proton treatment techniques. Therefore, the 
probability of inducing radiation pneumonitis and cardiac mortality by proton 
treatment techniques are very low. This probability of inducing late effects by photon 
treatment techniques is also very low. DVH values for the lungs show that there is little 
difference between proton and photon treatment techniques despite slightly higher 
maximum doses from protons than photons. The relative risk of cardiac mortality and 
DVH metrices for heart show that the heart is much spared by the proton treatment 
techniques compared to photons.  
Conclusion:  Protons treatment techniques are better than photons in sparing normal 
tissues based on different parameters such as NTCP and relative risk of cardiac 
mortality for the lung and heart, respectively. Additionally, proton therapy does not 
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«Radio therapy is ‘a bad but necessary’ treatment for pediatric cancer.” [1]. Radiation 
is a major contributor for late effects but also increases the rate of survival of children 
with cancer. In radiotherapy, the dose is delivered to the tumour to kill the cancerous 
cells. This is  in the form of energy deposited by ionization radiation, aiming to deliver 
a high radiation dose to the tumour volume while sparing the surrounding 
normal(healthy) tissue by keeping the dose here minimal[2]. The late effects due to the 
radiation dose to normal tissues can be decreased by the introduction of proton beams. 
Proton beam therapy may deliver 60 percent less radiation to healthy tissue around the 
target site compared to conventional photon radiation [3].     
Even if the introduction of protons improves the treatment of pediatric malignancies, 
the role of photon therapy to treat child hood cancer is still crucial. 
1.1 History and status of Radiotherapy  
In 1895, X-rays were discovered by Wilhelm Conrad Röntgen. This discovery opened a 
door to treat malignant and benign tumors, and then after one year, the rays were used 
to treat breast cancer without detailed knowledge of the physical properties and 
biological effect of the rays.  
The discovery of radium as a source of radiation in 1898 by Maria Sklodowska-Curie 
and her husband Pierre Curie which was followed by the report on physiologic effects 
of radium rays motivated scientists to study and use x-rays and radium in medicine. At 
this period skin cancers were the most frequently treated because of low penetration of 
the radiation into tissue. 
In 1910s, the new device, Coolidge tube was developed which was able to emit high 
energy x-rays to treat deep cancers. However the  results in the cancer treatment was 
very poor in comparison to the side effects[4]. 
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After establishment of The International Commission on Radiological Protection, 
ICRP in 1928, ionisation chamber was introduced in radio therapy, RT to measure 
radiation dose in 1932. In this period (1930 to 1950), there has been showed a scientific 
progress in treating cancer due to the use of Brachy Therapy and Electron beam 
Therapy. Besides, the introduction of cobalt teletherapy and linear accelerator helped 
to treat deep tumours with better skin sparing. Currently, it is common for cancer 
patients to be treated by either Internal or External Radiotherapy. However, the most 
common RT is External Radiotherapy which include Photon and Proton therapy.  
Photon therapy is a radiation therapy that uses x-rays or gamma rays produced by a 
linear accelerator(linac). The radiation dose is delivered at the surface of the body and 
goes into the body and reaches the tumor [5].This radiation therapy modality has 
changed in a sense of  delivery techniques through time and uses advanced technology 
such as multi-leaf collimator, intensity -modulated radiotherapy(IMRT) and image 
guided radiotherapy (IGRT). Despite advanced radiation-delivery techniques, it has a 
limitation to deliver tumor killing radiation dose while minimizing the dose to adjacent 
healthy tissues. Due to this limitation of photon therapy, there is currently a high 
interest in the use of the proton beam radiation therapy. Proton therapy is a type of 
external beam radiation therapy that use ionizing radiation produced by particle 
accelerator which typically produce70 to 250 MeV. 
 Proton therapy uses streams of protons to kill tumor cells[5]. This treatment technique 
can reduce the amount of radiation to healthy tissue near the tumor. To benefit proton 
therapy patients Pencil beam which composed Intensity Modulated Proton Therapy, 
IMPT and scanning beam are utilized. Pencil beams are very effective in treating the 
most complex tumors like brain, eye and cancer in children while effectively in sparing 
normal healthy tissue or Organ At Risks, OARS. Even if proton beam therapy is 
effective in delivering dose to the target and sparing the normal tissue, this therapy is 
an expensive technology.  
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Even if RT is effective for local control and plays an important role in the management 
of childhood cancer, with the primary aim of achieving the highest likelihood of cure 
with lowest risk of radiation induced morbidity, children are vulnerable to RT related 
effects affecting normal organ functions[6]. The normal organ or tissues are affected 
due to exit and entry dose.      
1.2 Project objectives/motivation 
Even though techniques such as intensity modulated radiotherapy (IMRT), proton 
therapy (PT) and intensity/ volumetric modulated radiotherapy (VMAT) has allowed 
for improved dose conformation to the target[7], normal tissue damage can-not be 
completely avoided  because the doses necessary to achieve tumour control usually 
overlap  with those that can cause complications. Therefore doses that are delivered to 
OAR (organ at risk) may have post treatment effects[8]. The range of adverse effects 
seen in children is different from  adults, in part due to the typical body sites affected 
by childhood cancer, but children are also more radiosensitive compared to adults [9]. 
The possible late effects or endpoints and the amount of dose received by organ at risk 
is also dependent on the type of treatments. 
The main objectives of this thesis are to compare the doses to organ at risk from proton 
and photon therapy of Norwegian pediatric cancer patients, selected for proton 
treatments abroad and to further evaluate the potential in risk of complications for 
selected end points.   
According to different research such as [6, 10], Proton therapy has a clear dosimetrtic 
advantage over photon therapy to treat pediatric malignancies. However, having dose 
conformity and dose distribution to normal tissue may not decrease toxicity. Some 
research show that no benefit is seen in hematologic toxicity, alopecia, fatigue and 
growth impairment if patients are treated by either of the two treatment techniques. 
Besides, a recent publication[11] shows that proton therapy does not improve dose 
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volume indices for the lungs but the again other recent publication show that the 




2. Physics of radiation therapy 
2.1  Interaction of Photons. 
Photon beam and energy. 
Photon beams are γ-rays. Those beams are one of the constitute of electromagnetic 
radiation. In context of radiation therapy, photons are considered like particles rather 
than waves. The energy that is carried by photons is given by Ε=հѵ, where h is 
Planck’s constant and v is the frequency.  
Photon attenuation 
A photon beam produced from an accelerator or radioactive source is attenuated as it 
traverses matter. The attenuation is due to interaction such as absorption and scattering 
and the number of photons,𝑁, after traversing a certain thickness, 𝑥, of material given 
by:    
      𝑁 = 𝑁𝑜𝑒
−µ𝑥     (2.1)                                                                                              
Where µ is the linear attenuation coefficient (units per unit distance) and its value 
depend on the traversed material and the energy of the photon beam.  
 Photon interactions with matter 
The attenuation of photon beams primarily caused by five types interaction. These are: 
photodisintegration (only important at very high photon energies(>10MeV)), coherent 
scattering, the photoelectric effect, the Compton effect and the pair production.  The 
latter four process can be represented by its own attenuation coefficient which varies 
in its particular way with the energy of photon and with atomic number of the absorbing 
material[13]. The total attenuation coefficient for these processes is given by:  
    µ 𝜌⁄ = 𝜎𝑐𝑜ℎ 𝜌⁄ + 𝜏 𝜌⁄ + 𝜎𝑐 𝜌 ⁄ +  𝜋 𝜌⁄     (2.2)  
6 
 
where 𝜎𝑐𝑜ℎ, τ, 𝜎𝑐 and π are attenuation coefficient for coherent scattering, photoelectric 
effect, Compton effect and pair production respectively. 
Photodisintegration. 
The process of emission of one or more nucleons during high- energy photon interacts 
with atomic nucleus is called photodisintegration. However, during this process mostly 
likely emission of neutrons occur. Because the rest energies of many nuclei are known 
for a very high accuracy, the photodisintegration process can be used as basis for 
energy calibration of machines producing high-energy photons[14].  
 2.1.3.1 Coherent scattering. 
Coherent scattering interaction occur when low energy photon (<10 keV) interacts with 
high-atomic-number of materials. Since the photon’s energy is below the binding 
energy of the electrons of the materials, the photon can-not liberate the electron from 
its bound state; therefore, there is no energy transfer from photon to electron. While 
the low energy photon passes near the electron, the electron setting in oscillation. This 
oscillating electron emits an energy with the same frequency as incident photon, 
similarly, the scattered X-rays have the same wavelength of the incident beam. This 
indicates that there is no energy absorption by the medium. The only effect during this 
process is the change of directions (scatter) of photon or scattering of photons at small 
angles. As other photon interaction process, coherent scattering is represented by its 
attenuation coefficient, which varies in its particular way with energy of photons and 
with atomic number of the absorbing material. The mass attenuation coefficient of 
Coherent scattering, 𝜎𝑐𝑜ℎ 𝜌⁄  is proportional to Z/(hv)   
2.1.3.2 Photoelecric effect. 
Unlike coherent scattering, a photon is absorbed by an atom and as result, one of its 
orbital electrons is ejected during the photoelectric effect interaction. The electron that 
is ejected (photo electron) has a kinetic energy which is the difference of the photon 
and binding energy of the electron(հѵ − 𝐸𝑏). Photoelectric effect is probable if the 
incident photon energy is equal to or slightly greater than the binding energy of the 
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electron. The probability of photo electric effect (mass photoelectric coefficient) is 
strongly dependent on atomic number. This strong dependence on atomic number is 
put considerable use in diagnostic imaging as it provides clear differentiation between 
tissues with different atomic number as well as, or in the absence of, differences in 
physical density[13].  
 
Fig.2.1 illustration of photoelectric effect[14] 
2.1.3.3 Compton effect  
In this interaction, the incident photon makes an interaction with atomic electron or 
free electrons. The photon transfers some of its energy in the form of kinetic energy to 
the electron in order to overcome the electron binding energy and take off it from the 
atom; due to the transfer of energy to the electron, the photon has lower energy after 
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the interaction. Unlike photoelectric effect, there is no resonance effect during this 
interaction. In Compton effect, the photon likely interacts with outer most shell 
electrons, “free” electrons with binding energy much less than the incident photons. 
The electron that receives an energy from the photon is emitted at an angle θ whereas 
the photon with reduced energy is scattered at an angle Φ. During this interaction both 
momentum and energy are conserved. By applying the conservation of energy and 




     (2.3)     




.  Where, 𝑚𝑒𝑐
2 is the rest 
mass of energy. Similarly, the energy of scattered photon is given by: 
 հѵ, = հѵ𝑜
1
1+𝛼(1−𝑐𝑜𝑠𝛷)
     (2.4) 
where, հѵ, is the energy of scattered photon.                                            
Unlike photoelectric effect, Compton interaction does not depend on the atomic 
number of the absorbing material since the interaction involves essentially free 
electrons in the absorbing material. This indicate Compton mass attenuation 
coefficient(𝜎𝑐 𝜌 ⁄ ) is independent of atomic number but depends on the number of 




Figure 2.2 Diagram illustration the Compton effect[14] 
2.1.3.4 pair production. 
A photon may interact with Coulomb field of an atom in the matter through pair 
production if and only if the photon energy exceeds 1.02𝑀𝑒𝑉. In this process the 
photon vanishes and creates a pair consisting of an electron  (𝑒−)  and positron (𝑒+). 
The excess energy above the threshold of 1.02MeV will be shared by the pairs as a 
form of kinetic energy. The probability of a photon being absorbed by pair production 
is proportional to the atomic number of the material traversed and for the energy range 





Figure 2.3 Diagram illustrating the pair production[14].  
Importance of photon interaction Vs Photon energy. 
As seen in the table the interaction of photons is dependent on energy regions. Photo-
electric dominates in lower energy region, but pair production dominates higher energy 
region as Compton dominate a region which is between the two regions where one 









Energy regions of domination for photo-elecrtic, compton and pair production 
interactions 
INTERACTIONS LOW Z(WATER) 
Photoelectric < 30keV 
Compton 30keV to 25 MeV 
Pair production >25MeV 
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Figure.2.4 the energy range at which photoelectric effect, Compton effect and pair 
production are dominant in water[13]. 
2.2 Interaction of Proton. 
Protons are considered as heavy charged particles since their rest mass of proton 
938MeV is much larger than the rest mass of electron, (0.51MeV). 
Protons interact primarily through inelastic Coulomb scattering with atomic electron. 
This interaction causes ionization and excitation and the protons lose a small amount 
of energy in each of numerous interactions passing through matter. Protons may also 
interact with the atomic nucleus through elastic or non-elastic scattering[14]. In elastic 
scattering, the kinetic energy of the proton that is transferred to internal structure of the 
nucleus is unchanged; implies the kinetic energy is conserved. Elastic scattering leads 
to a broadening av proton beam and leads in general to a less accurate dose deposition 
with depth in proton therapy. In non- elastic scattering the kinetic energy is not 
conserved besides the nucleus may fragmented or left in excited state. While charged 
particles interact with atomic nucleus, bremsstrahlung, radiative loss of energy is also 
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expected or occur. Compared to interaction via inelastic Coulomb scattering, 
bremsstrahlung is negligible. Because, bremsstrahlung loss is inversely proportional to 
the square of the incoming particles mass, proton. 
 
Figure 2.5 Schematic illustration of proton interaction mechanisms: (a) energy loss via 
coulombic interaction, (b) deflection of proton trajectory by repulsive Coulomb 
scattering, (c) removal of primary proton and creation of secondary particles via non-




Bethe-Bloch formula and energy loss rate. 
The loss of energy by proton or other charged particle in elastic Coulomb scattering 















− 2𝛽2 − 𝛿 − 2
𝐶
𝑍
]   (2.5)  
  
Parameters in Bethe-Bloch 





𝑟𝑒, classical electron radius Ѵ, the velocity of incident 
particle  




, energy per unit length. 
𝑚𝑒, mass of electron δ, density correction 
c, the speed of light C, cell correction 






z, the charge of incident 
particle  
A, the atomic number of the 
absorbing material. 
Z, atomic number of absorbing 
material. T 
I, mean excitation potential  
Table2.2 Bethe- Bloch formula’s parameters. 
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Bethe- Bloch formula indicates that the energy loss per unit length or stopping power 
depends on velocity and the charge of incident particle not on mass. The energy loss is 
inversely proportional to the square of the velocity (𝛽2) and directly proportional to 
the square particle charge (𝑧2 ) 
Linear energy transfer (LET) 
LET is the amount of energy deposited by ionization radiation along the particle track 
or in a matter and measured in [𝑘𝑒𝑣 µ𝑚⁄ ]. LET is commonly used to distinguish 
between ionizing radiation in relation to radiobiology; radiation having high LET (such 
as low-energy protons and alpha particles) will generally lead to greater biological 
effect than low LET radiation (photons, electrons and high-energy protons).  
Range  
As the protons interact with matter, they lose energy continuously since the matter is 
ionized by the protons during the interaction, this makes the protons to decelerate and 
finally stops. The finite distance travel by protons through a matter before they come 
to rest is known as Range. Since the difference in loss of energy by individual protons 
are very small, range is defined for proton beam not for a single particle. The proton 
range scale is roughly proportional with the square of proton energy since protons lose 
energy rapidly when interact with the traversing or absorbing matter. The range of 







     (2.6) 
where ϵo is primitivity of free space, me mass of electron, E is the energy of the 
incidence particle, na is Avogadro number, Z and M is a charge and mass of traversing 






  The Bragg peak is the maximum energy deposition with depth for proton which is 
results due to a sharp increasing in stopping power as protons decelerate down in 
material. This energy deposition with depth and the continuous energy loss of the 
protons while the protons traversing the matter is described by depth dose curve as 
shown in the figure2.6.   
                      
Figure 2.6. Schematic depth dose curve. Bragg peak of 60MeV protons in water[13] 
Energy straggling. 
The accumulation of small variations in energy loss of individual protons is called 
Energy straggling or range straggling which is a physical process that strongly governs 
the shape of a Bragg curve[15]. This physical process is helpful to understand the 








Figure 2.7. Relative fraction of the fluence in a broad beam of protons remaining as a 
function of depth z in water. The gradual depletion of protons from entrance to near 
the end of range is caused by removal of protons from nuclear reaction. The rapid fall 
off in the number of protons near the end of range is caused by ions running out of 
energy and being absorbed by the medium. The sigmoid shape of the distal falloff is 
caused by range straggling or by stochastic fluctuation in the energy loss of individual 





2.3    Dosimetry    
     Absorbed dose 
Absorbed dose represents the energy deposited in a mass by ionization radiation. It is 
defined as:   
𝐷 = 𝑑𝐸 𝑑𝑚⁄  , where D is absorbed dose, 𝑑𝐸 is the energy deposited and 𝑑𝑚 is the 
small mass. The unit of absorbed dose is Gray (𝐺𝑦) which quantifies energy deposition 
in joules per kilogram.     
     Equivalent dose and effective dose. 
Different degrees of biological damage can be produced by different types of radiation 
even if the absorbed dose is the same. The equivalent dose measures the risk the 
exposure of ionization radiation. 
Equivalent dose is the product of absorbed dose and radiation weighting factor. 
Equivalent dose(𝐻) = 𝐴𝑏𝑠𝑜𝑟𝑏𝑒𝑑 𝑑𝑜𝑠𝑒 (𝐷) 𝑋  𝑅𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛 𝑊𝑒𝑖𝑔ℎ𝑡𝑖𝑛𝑔 𝐹𝑎𝑐𝑡𝑜𝑟(𝑊𝑅). 
The unit of equivalent dose is Sieverts(𝑆𝑣) and Radiation weighting factor is 
dimensionless which is depends on the radiation energy distribution through the tissue.  
Effective dose accounts for varying biological effects of different types of radiation on 
a particular tissue types or organ[14].   
Effective dose(𝐻𝐸) = ∑ 𝑊𝑇𝐻𝑇, where  𝑊𝑇 is weighting factor of the tissue and  𝐻𝑇  is 
the mean equivalent dose received by the tissue.    
     Biological effects of radiation  
Exposing a body or an individual to a radiation leads to absorption of energy. This 
absorption can cause ionization and excitation. Besides, the absorption may cause a 
chemical change that form free radicals. This change that is caused by absorption may 
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bring a variety of biological effects in the body or individual, depending on the dose 
and where the dose is deposited. 
People may receive radiation from different sources such as from sun and Cancer 
treatments. During Radiotherapy treatment, patients’ body is exposed to ionization 
radiation. Since, RT uses ionization radiation to target and kill tumour tissue, but 
normal tissue can also be damaged, leading to toxicity[16]. Even if Intensity-
Modulated Radiotherapy is used, there is still possibility to normal tissue toxicity. This 
effect, the effect that is produced by RT is classified as early radiation effect, late 
radiation effect and consequential radiation effect.  
The early radiation effects are observed within weeks after the radiation exposure, e.g. 
within the first 90 days after the start of radiation therapy. This effect found in turn 
over tissues, like bone marrow, epidermis and gastrointestinal tract. 
The late radiation effect is a chronic and the effect is found in tissues like Vascular and 
connective tissue components and consequential effects develop in situations where 
early radiation responses are associated with breakdown and loss of physiological 
protective barrier against mechanical or physical stress[17]. This effect found in oral 
cavity, Oesophagus, small and large intestine and rectum. This change, radiation effects 
are expressed in the person who exposed radiation but there is also a change that may 
not necessarily express in the individual who exposed to the radiation, but the effect 
can be transfer to individual’s offspring. Such types of effect called Stochastic 
hereditary effects. The effects that is caused by this type of change could e.g. be a 
genetic defect. If the absorption of radiation produces an effect in the form of cancer 
in exposed individual, such effect is called stochastic somatic effects. The probability 
of stochastic somatic effects caused by radiation increases with dose. However, it is 
difficult to be certain that high dose exposure can cause cancer since the cause of the 
cancer also be another (like hereditary). If the level of the dose exceeds the threshold 
dose level, the effect of radiation can be acute and hazardous. Such effect is called Non-
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stochastic somatic effects or deterministic. This acute effect is expressed on exposed 
individuals in the form of vomiting, hair loss, sterility and diarrhoea. 
Since radiation exposure has negative consequences, International Commission on 
radiological protection (ICRP), set the standard limits to avoid or minimizing the risk 
radiation exposure.   
                            
Figure. 2.8.  Schematic illustration of radiation interaction  and its effects [13]. 
     Dose deposition.   
As photon travel through a matter, there is high energy deposition (Linear energy 
transfer, LET) at the iterance of the matter and LET decreases exponentially with depth 
through the matter. However, protons deposit less energy in a matter while they pass 
through it until reach the Bragg peak where the maximum proton energy deposited. 
This property makes proton to increase the concentration of dose to the tumor and 
decrease the concentration of dose to healthy tissue as seen in figure 2.9. This makes 





     Photons vs protons in tumors and tissues.   
The physics of photons results in substantial exit dose downstream from the target, 
tumor which is a physical limitation of photon beam (Figure 2.9). Protons travels 
through tissue quickly and stop abruptly when reaching at specific depth and deposit 
most of their energy at the end of their path known as Bragg peak; unlike photons which 
deposit a large amount of their energy at close to their entrance to the region proximal 
to the target. Before the Bragg peak the deposited dose may be 30% of the Bragg peak 
maximum dose and at Bragg peak, majority of energy deposition occur then the dose 
falls to zero, yielding a nearly non-existence exit dose. The integral dose with proton 
therapy can be as much as  60% lower than photon beam techniques[18]. Thus, proton 
therapy delivers radiation to tumors and areas in every close proximity decreasing the 
integral radiation dose to normal tissues and theoretically avoiding collateral damage. 
Despite Protons have an advantage over photon with fundamental issue i.e. the 
capability of being stopped at tumor and has low exit dose, protons are much more 
sensitive to tissue density as they pass through different tissues. Likewise, at greater 
depths the lateral margin of proton beam become less sharp due to considerable 
scattering[19]. Therefore, any change in tissue composition, organ motion, alteration 
in bone position from one treatment to the other can affect the target coverage and dose 
to surroundings. the disparity of dose distribution due to tissue heterogeneity is 
corrected by oncologist by adding a margin of uncertainty, meaning that beam is 
designed to overshoot the target to guarantee good coverage[20]. However, this could 




Figure 2.9. Comparison of relative depth dose distribution of photons versus protons 
while both beams interact with tissues and tumors[18] 
2.4 Treatment planning. 
Margin concepts. 
The definition of tumour and target volumes for radiotherapy is vital to its successful 
execution since radiotherapy is a localized treatment[21]. There are several types of 
tumour/ target volume definition. The first is a volume that shows the position and 
extent of gross tumor, this volume is called Gross Tumour Volume (GTV). The second 
is a volume that contain GTV plus a margin for sub -clinical disease spread which 
therefore can-not be imaged; this is called Clinical Target Volume (CTV)[21].Planning 
Target Volume(PTV) is the third volume which includes GTV, CTV and margins 
account for set up errors and possible geometric variation. In addition, critical normal 
tissue structures or Organ At risk (OAR) must be considered during treatment planning, 
to ensure that organs can-not receive higher than safe dose. 
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Figure.2.10. Diagram to illustrate the main radiotherapy planning volumes, taken from 
ICRU report 50[21].  
Dose volume Histogram and Dose metrices. 
The dose volume histogram (DVH) is a graphical representation of dose with in 
structures and it relates the amount of dose that received by the tissue and volume of 
the tissue. DVH can be useful to derive volume and dose metric. Volume metric 
(Vx[GY ]) represent volume of the structure receiving ≥ x dose and the dose may be 
specified as a percent, relative to a reference dose and the desired volume may be 
specified in absolute units(cc) and percent. Dose metric(Dx) represent minimum dose 
received by X% of the organ[22].     
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Radiobiology is the study of how ionising radiation affects living matter[23]. This 
branch of science which combines the basic principle of physics and biology and is 
concerned with the action of ionizing radiation on biological tissues and living 
organisms. [24]  
3.1 Ionizing and non-ionizing radaition. 
An energy that is emitted in the form of energy or particle and can propagate through 
a medium or a space is called radiation. Radiation can be classified as ionizing and 
non-ionizing. Ionizing radiation can ionize a matter either directly or indirectly, but 
non-ionizing radiation can-not ionize a matter. Charged particles (electrons, protons, 
alpha particles and heavy ions) and neutral particles (photons and neutrons) are directly 
and indirectly ionizing radiation respectively.  The quality of ionizing radiation beam 
is defined by LET. Typical therapeutic ionization radiation beams are:5-20Mv photons, 
5-20MeV electrons or protons, the Let increases with decreasing energy as explained 
by the Bethe-Bloch equation.    
3.2 Relative biological effectiveness(RBE). 
The number of ionized biomolecules produced per unit dose of protons, heavier 
charged particles and X-ray is similar but the resulting biological effects substantially 
differ[25].The difference in biological effectiveness such as cell killing, tissue damage, 
mutation and carcinogenesis are characterized by RBE which is the ratio of the dose of 
reference radiation (typically photons) to produce a specified effect to the dose of test 
radiation to the same effect. 
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Figure 3.1 The fraction of cells surviving a particular dose of X-rays is larger than the 
fraction of cells surviving the same dose of charged particles such as protons and 
carbon ions[25]. 
In proton therapy a constant RBE of 1.1 is assumed clinically. The prescribed absorbed 
dose in proton therapy is then slightly lower than for photon therapy. The RBE-
weighted dose can be calculated as: 
RBE-weighted dose = 1.1 x absorbed dose. 
The units of RBE-weighted dose is Gy (RBE)   
3.3 Cells and irradiation.  
Cells are radiosensitive. When cells are exposed to ionizing radiation, biological 
damage of cells function occur.  This biological damage of cells functions mainly from 
damage to DNA. When this radiation interacts with DNA, it makes DNA’s either single 
or double strand to be broken. The double strand DNA breaks occur when enough 
energy (LET) is deposited in the DNA. Damage of the DNA of the cell can cause the 
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cell of death or genetic mutation that may lead to cancer induction 
(Carcinogenesis)[26].  . 
3.4 Linear quadratic model(LQ) 
The LQ model is the most often used cell survival model which relates the fraction of 




Figure 3.2. The linear quadratic model with different parameters. For high LET, the 
cell survival curve is almost an exponential function of dose and for low LET, the 
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survival curve shows the initial slope followed by shoulder region and become nearly 
straight line [27].   
The survival probability of cell, 𝑆(𝐷) following to a single exposure dose, D radiation 
is described as: 
𝑆 = 𝑒𝛼𝐷−𝛽𝐷
2
, where α and β are parameters describing the cell’s radiosensitive and D 
is the dose to which it is exposed.   As the survival fraction is plotted against dose in 
log scale which is illustrated in figure 3.1, it shows α dominates the initial region at 
low doses and followed by increasing curvature as a quadratic β more dominant. The 
degree of curvature is frequently defined in terms of 𝛼 𝛽⁄  ratio in Gy. This ratio 
corresponds to the dose at which the linear and quadratic contribution are equal. Thus, 
cells with high 𝛼 𝛽⁄   ratios see relatively constant rate of cell killing with increasing 
dose, while those with low 𝛼 𝛽⁄  ratio shows a pronounced curve[28].      
3.5 Therapeutic ratio. 
Therapeutic ratio shows the relationship between tumor control and the likelihood of 
normal tissue complication or morbidity. The balance between the probability of tumor 
control(TCP) and the risk of normal tissue complication, NTCP is a measure of 
therapeutic ratio of the radiotherapy treatment[8]. 
Tumour control probability(TCP). 
TCP is the probability that a given dose of radiation will provide eradication of 
biological cells of tumor. TCP is described by a dose-response curve which is defined 





Normal tissue control probability(NTCP). 
The probability that a given dose of radiation will cause an organ or structure to 
experience complication is called NTCP.As TCP, a dose response curve which is 
defined by sigmoidal function describe NTCP. 
To achieve a high probability of tumor control at low NTCP is the aim of radiotherapy. 
 
Figure 3.3 Idealized -response curve. For increase in dose from level 1 to 2 there is 




4. Materials and methods. 
4.1 Patient data and treatment planning 
Patient data. 
Twelve pediatric tumour patients (6 Medulloblastoma, 3 neuroblastoma, 2 Ewing 
sarcoma and 1 Rhabdomyosarcoma, age range 2-16 years) were included in this thesis. 
These patients, 8 males and 3 females were treated with protons in University of Florida 
Health proton therapy institute in America between 2014 and 2016; and one 
Medulloblastoma patient was treated in Heidelberg Ion beam Therapy Center in 
Germany in 2015. 
For the purpose of this thesis, for each patient, VMAT plans were used for comparison 
to the delivered PT plans. Dose-volume histogram (DVH) extraction for target volumes 
and organ at risks was performed in Haukeland University of Hospital.  
Table.4.1. Patient and Tumuor characteristics (n=12). M=Male, F= Female, Age = Age 







Medulloblastoma P2 Brain/CSI 54 
Medulloblastoma P3 Brain/CSI 54 
Medulloblastoma P5 Brain/CSI 54 
Medulloblastoma P6 Brain/CSI 54 
Medulloblastoma P9 Brain/CSI 54 
Medulloblastoma P10 Brain/CSI 54 
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Neuroblastoma P7 Abdomen  21 
Neuroblastoma P11 Craniospinal  21 
Neuroblastoma  P12 Craniospinal 21 
Ewing sarcoma P4 Abdomen 54 
Ewing sarcoma P8 Abdomen 50.4 
Rhabdomyosarcoma P1 Abdomen 50.4 
RT planning, Treatment techniques and delivery. 
The patients were treated with protons and re-planned in VMAT retrospectively at 
hospital in Norway for the purpose of comparing the delivered proton plans. The 
patients were treated with protons, either passive scattering or IMPT, the re-plannings 
were done with photons beam data from Varian true beam and Elekta synergy. and the 
patients were also CT scanned in treatment position; for treatment planning. The radio 
therapy treatment plans were calculated using the Eclipse treatment planning platform. 
Among six Medulloblastoma patients, for five patients 23.4 Gy was prescribed to the 
entire PTV and additional 30.6 Gy to the boost PTV; therefore, the total tumour dose 
54Gy was delivered in 30 fractions. Similarly, for one patient also the prescribed dose 
was 36Gy and additionally, 18Gy was given to Boost PTV. The total tumour dose for 
this patient also 54Gy in 30 fractions. In order to allow uniform dose distribution tissues 
which are parts of central Nervous system (CNS) are considered as a secondary target 
in Medulloblastoma patients since they found close to PTV. For Medulloblastoma 
patients, all protons plans were delivered 3-7fields using 3mm margins for the P 
TV[29] .   
The three Neuroblastoma patients were prescribed total dose of 21Gy with 14 fractions. 
For these patients, the clinical target volume, CTV include the GTV plus anatomical 
32 
 
confined 1.0-1.5cm margin.  The two Ewing sarcoma patients were prescribed the total 
dose of 50.4Gy and 54 Gy. For the former, the total dose was delivered in 28 fractions 
whereas for the latter, the total dose was delivered in hyper fractionated RT method, 
i.e. the patient received 1.5Gy two times a day in 18 fractions. For Ewing sarcoma, 
there are two GTVs (GTV1 and GTV2) and the CTVs include GTV plus 1cm with high 
threshold to reduce the volume for pushing margins. The prescribed dose for 
Rhabdomyosarcoma was 41.4Gy but additionally 9Gy was delivered for to boost PTV. 
Therefore, 50.4Gy was the total dose prescribed dose. As Ewing Sarcoma, the RMS 
plan also contain two GTVs: GTV1 and GTV2.The former consisted pre- chemo tumor 
accounting for pushing margins and infiltrating margins that recede. The latter 
consisted the post chemo nodes, pre surgical disease. 
The planning goal which is normally 99% of the prescription dose to the CTV target 
volume but most importantly the target dose of the photon plan was scaled to fit the 
CTV of the delivered proton treatment.  
Target volume, PTV and OAR delineation for all patients were done at treating institute 
besides, all structures were reviewed by an experienced oncologist.  
Doses for OAR, DVH analysis  and Toxicity. 
Children treated with photon therapy and proton therapy for tumor have a risk that 
OARs can be delivered excess dose. DVH(Dose-volume-histogram) files of the 
patients was extracted, used and analysed in order to compare the doses; mean, 
maximum and minimum dose that was delivered for lungs and hearts. Besides, late 
acute and late toxicity, radiation pneumonitis and cardiac toxicity to lungs and hearts 
respectively; because of proton and photon therapy were compared and estimated based 
on Tolerance of Normal Tissue to Therapeutic radiation, NTCP values that was 





Normal tissue in the chest, including the healthy lungs, esophagus, heart, brachial 
plexus and spinal cord are often limiting the dose of radiotherapy[21]. To limit the dose 
to normal tissues, Radiotherapy-derived parameters are used. Such as V5 ≤65%, V20 ≤ 
30-35% and mean dose ≤ 7 Gy for lungs and for heart, the dose constraints V25 ≤ 10% 
are used. Based on those DVH metrices, the proton and photon therapy are compared, 
and the possible late effects also estimated too.    
Lyman-Kutcher-Burman( LKB) model for lung NTCP. 
The 3D dose distribution in a patient is used to determine DVH of organs which is 
normally the basis of calculating NTCP.  
In this thesis Lyman-Kutcher-Burman (LKB) model was used to calculate NTCP of 
lungs with the endpoints radiation pneumonitis. In general, LKB model are based on 
based on the equivalent uniform dose (EUD) which has a power-law relationship with 
local-dose effect relation. 





)𝑛   (1) 
Where Vi is the volume irradiated with dose Di in bin number I and Vtot is the volume 
of the organ.  
In this thesis a LKB based lung NTCP radiation pneumonitis  model by Seppenwoolde 
et al[30]  was used. In this model, n=1 is used, simplifying equation (1) to: 
𝐸𝑈𝐷 = ∑ 𝐷𝑖  
𝑉𝑖
𝑉𝑡𝑜𝑡
𝑖 = 𝑀𝐿𝐷   (2) 










𝑑𝑥   (3)   
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     (4)  
where  𝑇𝐷50 is the uniform dose given to the entire organ volume that results in 50% 
complication risk, m is a measure of the slope of the sigmoid curve represented by 
integral of the normal distribution[31].The value of 𝑇𝐷50 and m is 30.8Gy and 0.37 
respectively, according to Seppenwoolde[30].   
Relative risk of cardiac mortality. 
The risk of cardiac mortality was estimated based on extracted DVH data and model 
by Tukenova et al[32]   after RT, the NTCP values for heart were not calculated since 
the risk of radiation induced valvular diseases can-not be modelling using NTCP 
models only based on heart-dose volume distribution[33]. Therefore; instead of NTCP 
modelling relative risk of cardiac modelling (RR) is calculated.  
The dose effect relationship between the average radiation dose received by the heart 
and cardiac mortality was modelled with linear equation 1 of the excess RR(ERR)[32] 
Therefore, a linear relationship between the mean radiation dose to the heart and the 
relative risk of cardiac mortality is given by: 
𝑅𝑅 = 1 + 𝛼1𝐷      (5)    
where RR is the relative risk, H 
D is the mean heart dose, 𝛼1 the linear coefficient whose value is 0.6(95% confidence 
interval, 0.2-2.5)[34]. 




⁄     (6)     
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 where subscript Pr and ph denote Proton and Photon therapy respectively. 
Statistical analysis. 
For dosimetric comparison of proton beams to advanced radiotherapy (VMAT) 
dosimetric values, Vx and Dx are calculated and used based on the DVH of the lungs 
and heart of each patients and the bar graph that shows the mean dose comparison of 
the treatment techniques with their corresponding median value was plotted. In order 
to calculate NTCP values for both treatment techniques (for lung), (3) is used and based 
on the results of NTCP values both treatment techniques are compared, and possible 
radiation pneumonitis are also estimated. However, for heart, instead of calculating 
NTCP values, relative risk of cardiac mortality (RR) and the ratio of relative risk (RRR) 
of cardiac mortality were calculated, using (4) and (5) and based on the results the 
possible cardiac mortality is estimated as well as estimating which one of the two 
treatment plans have a likely possibility to produce toxicity. The Dose-Volume 
histogram of the lungs and hearts were not corrected for dose per fraction effect because 
the dose per fraction for the patients is 1.8Gy which is close to the standard 2Gy 
fractions. Therefore, the mean dose of the lungs from Dose-volume histogram was used 
as mean lung dose (MLD) to calculate NTCP and heart mean dose is used to calculate 




The aim of the treatment plan is to deliver prescribed dose to the tumour and minimum 
dose to the normal tissue, OAR. Based on this principle, the planning target volumes, 
PTVs coverage for photon were in a range of 99.7% to 100.1% and for protons, the 
coverage was in a range of 99.3% to 100%. The photon and proton treatments may 
therefore be expected to produce similar TCP values. The difference in treatments is 
therefore mainly in dose received by the OARs and will be presented in the following. 
5.1 Lung doses. 
DVH metrices  
DVHs for the lungs are shown for all patients in figure 5.1. In general, we see that the 
lung doses were highly heterogenous with maximum doses of several tenths of Gy for 
some patients. Moreover, as table A.1. shows, generally, the larger portion of the lung 
received a smaller amount of dose by proton than photon, but the smaller portion of the 
organ got smaller dose from photon than proton. In other words, protons spare the lungs 
for low to intermediate doses much better than photons whereas photons spare the lung 
for high doses slightly better than protons. This can be seen for patient P5 in figure 5.2.  
This is also clearly seen from DVH metrices such as V15, D40, and V5. 
Of 6 medulloblastoma patients, 108.41cc and 42cc of the lung of two patients, P2 and 
P5 respectively received 15Gy (V15) and more from proton but the same amount of 
dose was received by 99.44cc and 31.70cc of the lung of the same patient from photon. 
However, 40% of the lung of the two-patients received a minimum of 0.08Gy(D40) 
from proton and 4.99Gy(D40) and 4.8Gy(D40) from photon. As table A.1. shows also 
for the rest of three medulloblastoma patients has also the same trend with different 
dose metric parameter but with the same volumetric parameter. Similarly, V5 and 
V21.5 of lung for the neuroblastoma patients that is produced by photon is smaller than 
protons and D40 that is produced by photon larger than proton. And the same is 
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applicable for Ewing sarcoma patient with different DVH metric. The lung dose for 
three patients, P1, P4 and P7 were not discussed since the amount of dose that was 
delivered by both techniques is insignificant.      
 
Figure. 5.1 A plot that shows the dose to lungs by proton and photon with their 
corresponding treatments plan. Proton doses are indicated by solid lines while photon 




Figure.5.2. A plot shows the region (dose>12Gy, approximately) where photon’s dose 
to a medulloblastoma patient(P5) is less than proton’s dose(red) and the region 
(Dose>1.5Gy, approximately) where photon’s dose to a neuroblastoma patient(P11) is 
less than proton’s dose(blue). Proton doses are indicated by the solid lines while photon 
doses are shown using dashed lines.   
Mean dose. 
According to the bar graph, figure-5.2 below, the mean dose of photons is consistently 
greater than protons. Protons typically decrease the mean dose of lungs by almost a 
factor of two and for one medulloblastoma patient (P9) the dose is reduced almost by 
a factor of 5. For one neuroblastoma patient (P10), the mean dose for two plans have 
no significance difference whereas the mean dose for other patient is significantly 
decreases by proton. For Ewing sarcoma also the difference is visible i.e. proton 
decreases the mean dose significantly. One neuroblastoma, RMS and Ewing sarcoma 
patient have not been delivered significant dose by both treatment techniques.     
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As we see from Figure 5.2. the value of mean dose separating the higher half from the 
lower half of the dose, median of the mean proton is 2.3 Gy and photon’s is 7.2Gy. 
Figure 5.3. Comparison of mean dose of proton and photon to the lungs. The median 
mean doses are displayed in the last bars.  
 According to Tolerance of Normal Tissue to Therapeutic Radiation of Dr. Emami B 
et al [22], one Ewing sarcoma patient(P8) got a mean dose of 8.577Gy from proton  
therefore, the incidence of pneumonitis to be appeared  is between 5 and 10%. The 
incidence of pneumonitis to be appeared to this patient is 10% due to the delivery of 
radiation from photon. The incidence of pneumonitis to be appeared in these 4 patients 






Figure 5.3 and figure D.1 show that the maximum doses which were delivered to the 
lungs by protons is larger than photons for 7 of 9 patients. The value of the maximum 
dose for the other two patients from photons are slightly larger than protons. Therefore, 
the maximum dose values comparison and DVH metrices reveals that in terms of 
restricting maximum dose photons are better than protons. The maximum dose of the 
RMS patient(P1), one Ewing sarcoma(P4) and one neuroblastoma(P7) were not 
included since the dose is insignificant. 
 
 
Figure 5.4. Maximum dose comparison of photons and protons comparison for lungs. 





As table B.1. and figure 5.5 and 5.6. show, among 6 of medulloblastoma patients, the 
NTCP is decreased by a factor 2 and more by protons for 5 patients; even for one 
medulloblastoma patient(P9) NTCP is decreased by a factor of 4.7, from 0.0265 to 
0.0056, by using protons. For one medulloblastoma patient(P10) the NTCP value is 
produced by photon and proton is the same. Of 3 neuroblastoma patients proton 
reduced the NTCP value by a factor of 2.3 or more for 2 patients (p11 and P12). For 
one Ewing sarcoma patient the proton influence is the same as neuroblastoma patient. 
For one neuroblastoma, wing sarcoma and RMS patients the NTCP values are not 
included since the mean dose and therefore NTCP of those patients is insignificant. 
Generally, Proton’s NTCP value is much smaller than the photon’s for all type of 
pediatric malignancies patients and this confirm that protons, for the endpoint of 
radiation pneumonitis are more near to achieve the aim of radiotherapy i.e. achieving 







Figure 5.5. The plot that shows the NTCP model and compare the NTCP values (the 
probability of radiation pneumonitis) from protons(box) and photons(red). The 
probability of the patients to face radiation pneumonitis is less than 6% for all patients. 
The highest value is produced by photon whereas the highest probability of having 
radiation pneumonitis estimated from proton plan is 2.6%.  




Figure 5.6. Bar graph that show lung NTCP in % for the endpoint of radiation 
pneumonitis produced by photon and proton. The median of NTCP values are 
displayed in the last bars. 
5.2 Heart Dose. 
DVH metrices  
The dose to heart were overall lower from protons compared to photons (Figure5.9). 
As seen in the DVHs, protons gave little dose to parts of heart while for the photon 
plans, the heart dose varied more between the different patients. 
As table A2. shows the dose metrices V15 from protons for four medulloblastoma 
patients is less than from photons treatment techniques except for one patient (P9). For 
this patient, V15 is equal to zero from both treatment techniques. The dose constraints 
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for heart, V25 is equal to zero from both treatment techniques for all four 
medulloblastoma patients. The dose constraints for heart, V25 should less than 10%[35]. 
For one Ewing sarcoma patient the value of V15 is decreased by a factor of 9 by protons 
compared to photons. For this particular patient the value of V25 is different from zero 
for both treatment techniques but those values, 0.036% and 0.425% for protons and 
photons treatment techniques respectively is much smaller than the dose constraints 
value of heart(V25=10%); therefore, the patient can-not expect long term cardiac 
mortality and likely or no clinical gain is achieved for the patient by using protons 
instead of photons. 
V15 of neuroblastoma patients has similarity with Ewing sarcoma and medulloblastoma 
patients i.e. V15 of protons is much less than photon treatment techniques. For one 
Neuroblastoma patient (P12) proton reduced V15 from 10.54% to 1.33% compared to 
the photons treatment. 
For the RMS both dose metrices V15 and V25 are zero because the amount dose that was 
delivered by both treatment techniques were small.  Two medulloblastoma, one Ewing 
sarcoma and one neuroblastoma patients’ DVH metrices are not calculated because the 




Figure. 5.7. Dose Volume histogram for the heart for proton plans (solid lines) and 
photon plans (dashed lines). 
Mean dose.  
Over all Figure 5.8 below illustrate the photons doses to the heart are consistently 
higher than proton doses. According to the bar graph, the mean dose of protons for all 
pediatric patients is less than 0.8Gy whereas the mean dose from photons to 7 to 8 of 
patients greater than 3.5Gy i.e. only one patient received a mean dose which is less 
than 3.5Gy. The mean dose values for two medulloblastoma (P2 and P3), one Ewing 
sarcoma (P4) and one neuroblastoma (P7) patients are insignificant and therefore not 
included.   
As we see from the bar graph, the value of mean separating the higher half from lower 
half of the dose, median of the mean proton is 0.24Gy and photon’s is 7.8Gy.      
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Figure 5.8.  Comparison of mean dose of proton and photon for the heart. The median 
mean doses are displayed in the last bars. 
Maximum dose. 
As table D.1 shows among 8 pediatric malignancies patients the maximum dose which 
was delivered by photon to 7 patients is much larger than proton delivery but the 
maximum dose of one medulloblastoma patient (P6) that was delivered by photon is 
smaller than protons. The values of maximum dose for one Ewing sarcoma(P4) and 





Figure 5.9. Maximum dose comparison of photons and protons comparison for hearts. 
The median maximum doses are displayed in the last bars.  
Relative risk of cardiac mortality. 
 As seen in figure 5.10 relative risk of cardiac mortality that is produced by photon is 
greater than the value that is produced by proton. The result further summarized in 
table B.2. The value of relative risk of cardiac mortality that is produced by proton is 
less than 1.5 whereas the value that is produced by photon is almost greater than 3 
except for one RMS patient whose value is 1.357. The ratios, 
𝑅𝑅𝑝𝑟
𝑅𝑅𝑝ℎ
⁄  that was 
calculated by using equation (6) show that all values less than or equal 0.4 except for 
RMS patient. The ratio and individual values of relative risk of cardiac mortality shows 
that, according to the applied risk model, delivery of photon increases the probability 




Photon’s relative cardiac mortality values for medulloblastoma patients higher than the 
other patients. This indicate that, the medulloblastoma patients have a larger probability 
to face cardiac mortality than the other patients. Similarly, Proton’s neuroblastoma 
relative cardiac mortality values are larger than the other patients. 
 
Figure 5.10 the relative risk of cardiac mortality comparison. 
5.3 Doses for other OARs 
Dose for Lungs and hearts were discussed in detail but several other OARs were also 
delivered significant doses for all pediatric cancer patients. The results of those OARs 
were discussed by classifying the organs such as abdominal organ, CNS organs, sense 




The mean and median doses of photon that was delivered for abdominal organ such as 
stomach, liver, bladder, bowel (large and small) and rectum were larger than the same 
types of doses that was delivered by proton treatment techniques. Referring maximum 
doses which were delivered by both treatment techniques for those organs is variable; 
meaning for certain organs like rectum and bladder protons deliver excess maximum 
doses as shown in table D.1. 
Referring CNS organs like brain, cerebellum, hypothalamus and cerebrum, the mean, 
median and maximum doses that was delivered by protons larger than the doses that 
was delivered by photons treatment techniques for majority of pediatric cancer patients 
except the Spinal cord where mean and median dose from photon are dominant. 
Especially, for medulloblastoma patients the value of the doses, mean, median and 
maximum doses for OARs are high, this because of parts of Central nervous are 
considered as a secondary target as they found near to PTV and for allowing uniform 
dose distribution across the OARs. 
When parts of sense organs like cochlea (right and left) and retina (right and left), 
lacrimal gland (right and left) and lens (right and left) are considered, the mean, median 
and maximum doses that was delivered to parts of ear from photon is larger than 
protons whereas the doses to the parts of eye from proton is larger (table D.1). 
Organs located at thoracic cavity such as breast, thyroid gland and Oesophagus were 
delivered smaller dose by protons than photons for mean, median and maximum doses 
as shown in table D.1.  
The mean, median and maximum dose to kidneys (left and right) from photon treatment 
techniques is larger than proton’s dose for majority of malignancies patients.   
Even if, the dominancy of photon and proton interchanges for different dose values in 
retina (left) as shown in figure 5.11. for different pediatric cancer patients, the mean 
and the maximum doses which were delivered for retina (left) of the different 
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malignancies patient by proton is overall larger than photon (see figure 5.12. and figure 
5.13)  
 
                                  
figure 5.11 A plot that shows the dose for retina (left) by protons (solid lines) and 
photons (dashed lines). 
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figure.5.12 Comparison of mean dose of proton and photon to retina (left) for 
medulloblastoma patients. The median mean doses are displayed in the last bars.  
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Figure 5.13 Comparison of maximum dose of proton and photon to retina(left) for 
medulloblastoma patients. The median mean doses are displayed in the last bars.  
  For esophagus, the doses varied significantly between the patient, but in general, 
protons is shown to give some dosimetric advantage also for this OAR.  However, both 
treatments delivered relatively high dose to one Ewing sarcoma patient ‘s esophagus 








Figure 5.14. A plot that shows the dose to the esophagus by proton and photon with 
their corresponding treatments plan.  




Figure 5.15 Comparison of mean dose of proton and photon to the esopahgus. The 












Figure 5.16 Comparison of maximum dose of proton and photon to the esophagus. The 




6.1 Dosimeric and DVH metrics aspects. 
This study was conducted in order to compare the doses to OARs from proton and 
photon therapy for different pediatric cancer patients with radiotherapy to the thorax, 
abdomen and pelvis. In addition, to estimate and compare late morbidity based on two 
organ at risks, heart and lung. Mean, median, maximum dose, different DVH metrices 
and NTCP are useful parameters to evaluate the aim of RT which is to treat patients 
according to well defined risk groups in order to maximize cure rates and  side effects  
in survivor [10]. Even if delivering low doses for OAR can-not guarantee the normal 
tissues not having late effects, all included types of cancer OAR especially lungs and 
heart received a lower amount of dose from protons than photons. For example, one 
medulloblastoma patient’s lungs (P9) received 9.4 Gy and 1.89 Gy of mean dose from 
photon and proton respectively. Particularly, the amount of different doses (mean, 
median and maximum dose) that was received by heart from protons was too small. 
One medulloblastoma patients’ heart received 0.03Gy and 7.4Gy of mean dose from 
proton and photon treatment techniques respectively. Similarly, even if the amount of 
dose which was delivered by both treatment techniques to the heart was very small, the 
hearts of all types of malignancies received an even smaller amount of doses (mean, 
median dose and maximum dose) from protons than photons. This result, the 
dominancy of protons over photons by delivering small amount  mean and median 
doses agree with other different case studies[36, 37]. For the lungs the result that was 
found based on DVH metrices were slightly different from the comparison of the two 
treatment techniques based on doses. The lower dose-metrices like D2 and D40 show 
that protons are better than photons but the higher dose- metrices like V15, V18, and V5 
show that photon is better than protons. This confirms and agree with the advantage of 
proton beams over photon beams (IMRT) become apparent in the medium and low -
dose range (i.e. <50% of prescription isodose), where the superior over all dose-volume 
characteristics of proton lead to a significantly improved OAR sparing[38]. The 
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volume metric V20 and V5 are dose constraints for lung; meaning, dose constraints are 
parameters that can used to estimate the endpoints (i.e. late effects) post treatment or 
tolerance limit of the normal tissue. Based on the results of the dose constraint analysis, 
the patient will not experience radiation pneumonitis since the value of V20 is less than 
35% and V5 is less than 65%, for both treatment techniques. Results for heart has a 
difference from the lung’s DVH metrices; DVH metrices for lung show that for low 
dose protons were better than photons but for high doses the opposite was true. DVH 
metrices for heart confirmed that for high dose and low doses, proton spares the heart 
than photon. The dose constraints for heart, V25 is zero for both treatment techniques 
except for one Ewing sarcoma patient. The values were, 0.036% and 0.43% for Ewing 
sarcoma patient from protons and photons. This is much smaller than 10% which is the 
tolerance limit of heart and beyond this value the patient may experience cardiac 
toxicity but as the values from the patient shows that the patient has minimum 
probability to experience cardiac toxicity. The value of lower dose metrices like V25 is 
zero for most patients, this may happen because of the low amount of dose is delivered 
for the organ by both treatment techniques. 
6.2 Radiation Pneumonitis based on NTCP and cardiac 
mortality.  
As table B.1 shows that all values of NTCP which is produced by photon is larger than 
protons and the difference between photon’s and Proton’s NTCP is negative. Even if 
the lowest value of NTCP that is produced by proton and photon treatment techniques 
for medulloblastoma patients are equal, the highest value that is produced by photon is 
almost 2.5 times the highest value of Proton’s NTCP for these patients, this clearly 
shows that the organ, lung of medulloblastoma patients is spared by protons. Despite 
of the value of NTCP which was produced by protons for Ewing sarcoma (P8) patient 
is third highest of all NTCP values, this value is much less than NTCP value that was 
produced by the photon treatment technique. As medulloblastoma and Ewing sarcoma 
patients, the lung of neuroblastoma patients was spared by protons. 
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NTCP estimates the risk by modelling of a given side effects as a function of increasing 
dose to organ at risk/ probability of a given side effects as a function of increasing dose 
to  the organ at risk (OAR) or increasing volume with an OAR receiving a certain 
dose[37]; therefore, the relationship between MLD and the risk of RP is described by 
NTCP modelling like the LKB model which is used for in this work. According to the 
results based on the LKB model, the values of the NTCP which is produced by photons 
is larger than Proton’s. This indicate that probability of having RP is also increased 
more by photons than from protons. Even if photons increase inducing radiation 
pneumonitis, the probability of all patients to have RP is very low since the value is 
less than or equal 2.56% for all patients. 
The relative  risk of cardiac mortality is depends on the mean dose of the heart but 
cardiac mortality can-not be estimated by LKB model since the risk of radiation 
induced valvular disease can-not be dependent only on heart dose distribution[33]. 
However, according to the model used in this thesis radiation induced valvular disease 
only depend on heart dose distribution. Therefore, the radiation induced cardiac 
mortality was compared the ratio of the relative risk which between protons to photons. 
The last column of table B.2 show that the ratio is less than one. This implies that 




The values of mean, median and maximum doses show that by using proton 
treatment techniques the delivery of doses is smaller than for photon treatment 
techniques. Most OARs were spared by protons such as breast, esopaghus and 
Spinal cord but few OARs such as (Left and right retina), hypothalamus and lens 
were spared by photons compared to Protons treatment. Referring to DVH metrices 
for the lungs, photons is slightly better than protons for high dose region whereas 
protons are better than photons at low doses. For the heart, as different doses such 
as mean, median, maximum and DVH metrices show that proton clearly spared the 
heart compared to photons. Besides, photons gave a higher risk of radiation 
pneumonitis and cardiac mortality than protons. However, the values of doses from 
both photon and proton are much far less than the value of the dose tolerance limits 
of both organs therefore, the probability of the patients to experience late effects is 
still quite low, also for photons. Overall, this thesis shows that protons give several 
dosimetric advantages. However, in many cases it may be difficult to observe 
improved clinical outcome as the risk for radiation pneumonitis and cardiac 
mortality was relatively low for both proton and photon treatments 
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Appendix A  
DVH metrices for lung and hearts.  
 
 Table.A.1: DVH metrics of lung dose for proton and photon treatment plan. 
 
Patient type and patients Proton plan’s dosimetric 
values 
Photon plan’s dosimetric 
values 
Medulloblastoma D40[Gy] Vy[cc] D40[Gy] Vy[cc] 
P2 0.08 V15=108.41 4.99 V15=99.44 
P3 0.08 V18.5=240.24 8.139 V18.5=232.58 
P5 0.08 V15=42.00 4.80 V15=31.70 
P6 0.91 V18=94.678 8.44 V18=86.078 
P9 0.07 V20.6=81.54 8.78 V20.6=81.31 
Neuroblastoma D40[Gy] Vy[cc] D40[Gy] Vy[cc] 
P11 0.07 V5=36.12 0.61 V5=22.79 
P12 0.25 V21.5=24.97 5.33 V21.5=11.21 
Ewing sarcoma D40[Gy] Vy[cc] D40[Gy] Vy[cc] 














Table.A.2 DVH metrics of heart for proton and photon treatment plan 











Patient type and 
patients 
Proton plan’s dosimetric 
values 
Photon plan’s dosimetric 
values 
Medulloblastoma D2[Gy] Vy% / [cc] D2[Gy] Vy % /[cc] 
















RMS D2[Gy] Vy% / [cc] D2[Gy] Vy % /[cc] 
















Ewing sarcoma D2[Gy] Vy % / [cc] D2[Gy] Vy % / [cc] 
















Appendix B  
Table B.1.  NTCP comparison of proton and photon. 
N.B. ProtonMLD and photonMLD are the value of mean lung dose by proton and 
photon respectively. ProtonNTCP   and PhotonNTCP   are the values NTCP produced 





Patient protonMLD photonMLD ProtonNTCP PhotonNTCP ProtonNTCP-photonNTCP 
P2 2.286 5.565 0.0062 0.0134 -0.0072 
P3 4.105 8.4 0.0096 0.0246 -0.015 
P5 2.297 5.208 0.0062 0.0124 -0.0062 
P6 3.631 8.567 0.0086 0.0255 -0.0169 
P8 8.577 13.074 0.0256 0.06 -0.0344 
P9 1.889 8.75 0.0056 0.0265 -0.0209 
P10 1.364 1.463 0.0049 0.0050 -0.0001 
P11 1.363 4.815 0.0049 0.0113 -0.0064 




Table B.2 the values of relative risk of cardiac mortality of each patients for both 
protons and photons with their corresponding protons and photons with their 
corresponding ratio. 
Patients Rpr Rph Rpr / Rph 
P1 1.002 1.357 0.7378 
P5 1.118 6.045 0.185 
P6 1.379 6.138 0.2246 
P8 1.242 3.1 0.4008 
P9 1.019 5.454 0.1868 
P10 1.014 5.845 0.1734 
P11 1.169 3.924 0.2980 





Appendix C  
C.1. Patients data who were treated from different malignancies and with their 
corresponding treatment period.  




P1 RMS 2014 
P2 Medulloblastoma 2014 
P3 Medulloblastoma 2014 
P4 Ewing sarcoma 2015 
P5 Medulloblastoma 2015 
P6 Medulloblastoma 2015 
P7 Neuroblastoma 2015 
P8 Ewing sarcoma 2016 
P9 Medulloblastoma 2015 
P10 Medulloblastoma 2015 
P11 Neuroblastoma 2015 
P12 Neuroblastoma 2015 
 
C.2. The total dose which was delivered for patients by two treatment techniques and 




Patients Apparatus Number of 
fields for 
VMAT 
Proton plan Photon plan Total Dose 
(Gy). 
  
P1 Varian true 
beam STX 
2+1 Proton Plan sum 
VMAT 99 
50.4 
P2 Varian true 
beam STX 







6+1 Proton VMAT sum 
99 
54 
P4 Varian true 
beam STX 
2 Proton VMAT 99 54 
P5 Varian true 
beam STX 







6+2 Proton VMAT sum 
99 
54 
P7 Varian true 
beam STX 





P8 Varian true 
beam STX 
4 Proton VMAT 99 50.4 










P11   Proton Photon 99 21 





Appendix D  
D.1. Different types of doses, Mean, Median, and Maximum values that were delivered 
for different pediatric malignancies patients by proton and photon treatment 
techniques. 
N.B. P1 to P12 represents the patient’s number and Prmed=proton’s median which the 
median dose that was delivered by proton treatment techniques. Similar analogous is 
used for other abbreviation also. 
Prmea= proton’s mean, Phmed=photon’s median, phmea= photon’s mean, 
prmax=proton’s maximum, phmax=photon’s maximum. 
 (phmed-prmed), (phmea-prmea) and (phmax-prmax) is the difference of type of doses 
which were delivered by photon and proton treatment techniques.   
 
OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
bladder 42.14 42.13 41.50 41.55 42.86 42.74 -0.64 -0.57 -0.11
Bowel space 0.39 14.24 22.12 25.91 52.14 52.89 21.73 11.67 0.75
bowel large 6.61 0.00 19.17 21.04 51.47 51.69 12.56 21.04 0.22
bowel small 5.33 17.08 25.76 29.13 51.81 52.78 20.43 12.05 0.97
fermur left 0.00 2.83 16.28 16.31 36.37 30.17 16.27 13.48 -6.20
fermur right 0.00 0.23 15.75 15.86 16.03 23.14 15.75 15.63 7.11
Growth plate left 3.66 6.04 19.64 19.70 28.77 24.91 15.98 13.66 -3.86
growth plate right 0.01 0.45 15.47 15.72 7.80 21.03 15.46 15.26 13.22
heart 0.00 0.00 0.49 0.60 0.11 2.33 0.49 0.59 2.22
kidneyLt 1.52 10.55 5.57 8.66 45.72 49.09 4.06 -1.89 3.37
kidney rt 4.80 10.00 6.77 8.58 43.51 36.01 1.98 -1.43 -7.49
liver 0.00 1.08 6.22 8.79 42.55 42.32 6.21 7.71 -0.23
nerve roots 24.78 24.49 13.85 14.38 39.14 24.24 -10.93 -10.12 -14.90
rectum 22.95 25.13 20.24 24.65 42.75 42.69 -2.71 -0.49 -0.06
skin 0.00 2.28 7.77 7.85 42.32 41.31 7.77 5.57 -1.01
spainal cord 40.29 31.69 26.50 20.93 49.38 35.41 -13.79 -10.76 -13.97
stomach 0.00 3.62 18.77 19.54 50.65 50.32 18.76 15.92 -0.34
Zpevlvic vessel 42.40 44.25 41.95 43.71 52.14 52.14 -0.45 -0.54 0.00
Zaorta 49.03 47.14 49.83 47.11 51.57 52.01 0.80 -0.03 0.43
Zpost chemonode 51.16 51.17 51.00 51.00 51.74 52.08 -0.16 -0.16 0.34
Zpara-aortic 49.44 47.30 49.86 47.18 51.03 52.01 0.42 -0.13 0.98







OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
bones 23.39 23.11 23.96 24.04 56.21 54.57 0.57 0.93 -1.64
brain 24.84 29.18 24.54 30.00 5.22 56.93 -0.29 0.81 51.71
brainSupra tent 24.61 26.34 24.40 26.78 55.79 56.37 -0.21 0.44 0.58
brain stem 49.45 44.49 52.37 49.02 55.58 56.93 2.92 4.52 1.34
brainstemCore 48.87 45.21 51.91 49.52 55.34 56.91 3.03 4.32 1.57
brain stemsurface 50.62 43.77 53.25 48.58 55.59 56.93 2.63 4.81 1.34
cerebellum 57.62 48.08 53.52 50.14 56.22 56.89 -4.11 2.06 0.67
clip box 23.34 22.69 23.78 23.01 36.80 31.41 0.44 0.32 -5.38
cochlea LT 24.36 24.37 36.78 36.80 24.98 37.65 12.43 12.43 12.68
cochlea Rt 24.41 24.42 37.91 37.92 24.70 38.80 13.50 13.50 14.10
cord 23.42 23.57 24.01 24.25 47.92 45.97 0.58 0.67 -1.96
cribriform 24.51 24.53 24.48 24.47 25.05 25.16 -0.02 -0.06 0.11
Hippo head Lt 25.53 26.13 35.35 35.27 32.60 40.47 9.81 9.14 7.88
hippohead Rt 25.07 25.40 34.84 34.79 29.48 38.92 9.77 9.39 9.44
hippo Lt 28.51 29.79 35.11 34.79 43.19 45.79 6.60 5.00 2.60
hippoRt 34.18 33.62 37.82 39.84 34.18 33.62 2.02
Hippo Tail Lt 33.64 33.70 34.24 34.29 43.19 45.58 0.60 0.60 2.39
hippo tai Rt 32.51 31.97 32.41 32.33 37.82 39.84 -0.09 0.35 2.02
hippocampuslL 28.51 29.79 35.11 34.79 43.19 45.58 6.60 5.00 2.39
hypothalamus 25.00 26.05 25.72 26.05 38.90 31.54 0.71 0.00 -7.36
kidneyLt 0.00 2.22 6.19 7.66 23.42 23.00 6.19 5.44 -0.42
kidney rt 0.14 3.57 8.01 8.76 23.53 23.92 7.88 5.20 0.38
lacrimal Lt 22.30 18.95 18.07 17.93 23.13 22.09 -4.23 -1.02 -1.04
lacrimal Rt 22.91 20.86 17.79 17.99 23.40 23.81 -5.12 -2.87 0.41
lensRt 14.32 14.19 9.10 9.12 18.99 10.74 -5.22 -5.07 -8.25
lensLt 11.82 12.43 9.39 9.45 19.76 10.75 -2.43 -2.99 -9.00
lung Lt 0.00 1.92 3.39 5.12 25.32 24.25 3.39 3.20 -1.08
lung Rt 0.00 2.62 4.04 5.96 26.71 24.30 4.03 3.35 -2.40
lungs 0.00 2.29 3.73 5.57 26.71 24.46 3.72 3.28 -2.25
optichaism 0.00 0.00 26.58 26.55 0.00 26.93 26.58 26.55 26.93
optic nervLt 24.51 24.49 24.87 24.44 24.97 28.42 0.36 -0.05 3.46
optic nerveRt 24.40 24.41 24.18 23.99 24.94 28.13 -0.23 -0.43 3.20
parotid_L_cagr 18.40 17.53 21.73 20.87 24.34 31.41 3.34 3.34 7.06
parotid_R_cagr 22.33 20.04 22.32 21.84 24.22 32.13 -0.02 1.80 7.91
parotids 20.69 18.78 21.97 21.36 24.34 32.13 1.28 2.58 7.79
pitutary 24.84 24.84 30.63 30.64 24.91 31.70 5.79 5.80 6.79
retinaLT 16.92 15.65 14.20 14.39 24.42 22.35 -2.72 -1.26 -2.07
retina Rt 18.38 17.37 14.24 14.49 24.35 22.68 -4.14 -2.88 -1.67
spinal cord 24.03 30.47 25.37 30.88 54.07 51.51 1.34 0.41 -2.56
TemporalLobeLt 24.00 25.41 31.26 31.49 55.03 56.01 7.26 6.08 0.98







OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
brain 37.87 39.15 39.04 40.13 56.90 55.00 1.16 0.98 -1.90
brainSupra tent 38.00 39.58 39.85 40.66 56.90 55.00 1.85 1.08 -1.90
brain stem 39.95 44.06 38.26 43.28 55.43 54.89 -1.69 -0.78 -0.54
brainstemCore 40.74 44.40 38.69 43.61 55.41 54.97 -2.05 -0.79 -0.44
brain stemsurface 39.18 43.45 37.80 42.78 55.36 54.98 -1.38 -0.67 -0.37
cerebellum 37.94 38.51 36.64 37.28 55.92 54.85 -1.30 -1.23 -1.06
cochlea LT 37.98 37.99 35.94 35.95 38.40 36.24 -2.03 -2.04 -2.17
cochlea Rt 37.59 37.59 36.36 36.37 37.92 36.55 -1.23 -1.22 -1.37
cribriform 37.92 37.89 39.09 39.05 38.60 40.88 1.17 1.16 2.28
Hippo head Lt 41.32 41.50 44.41 44.45 46.88 50.43 3.08 2.95 3.55
hippohead Rt 38.67 38.66 43.45 43.16 39.56 47.05 4.78 4.50 7.49
hippo Lt 42.01 42.08 45.01 45.10 48.22 52.33 3.00 3.01 4.11
hippoRt 38.72 39.24 44.19 43.96 47.87 48.28 5.47 4.72 0.41
Hippo Tail Lt 44.32 44.38 47.74 47.78 48.22 52.11 3.42 3.41 3.90
hippo tai Rt 39.30 40.17 45.18 45.17 47.87 48.28 5.87 5.00 0.41
hypothalamus 47.14 47.21 50.03 50.04 55.06 54.52 2.89 2.83 -0.54
kidneyLt 0.00 2.07 7.43 8.81 36.15 33.14 7.43 6.74 -3.01
kidney rt 0.00 1.10 5.44 7.28 35.30 29.01 5.43 6.18 -6.29
lacrimal Lt 35.58 35.08 30.55 30.50 36.60 35.43 -5.03 -4.57 -1.17
lacrimal Rt 35.17 34.58 29.27 29.27 36.06 35.18 -5.89 -5.31 -0.88
lensLt 18.19 18.24 20.34 20.38 24.66 22.23 2.14 2.13 -2.43
lensRt 21.73 21.74 20.23 20.28 28.86 22.41 -1.50 -1.46 -6.45
lung Lt 0.00 4.09 6.12 7.90 38.97 37.76 6.11 3.81 -1.21
lung Rt 0.00 4.11 7.17 8.83 38.87 37.04 7.17 4.72 -1.84
lungs 0.00 4.11 6.57 8.40 38.97 37.76 6.57 4.30 -1.21
MastoidLt 36.26 36.29 35.87 35.31 37.93 37.17 -0.38 -0.98 -0.76
mastoidRt 36.08 36.11 35.25 34.68 37.80 37.34 -0.83 -1.43 -0.46
optichaism 38.41 38.40 41.83 41.88 38.57 43.24 3.42 3.48 4.67
optic nervLt 38.00 38.01 38.55 38.65 38.41 40.95 0.55 0.63 2.53
optic nerveRt 37.91 37.91 38.70 39.03 38.30 41.43 0.79 1.13 3.13
parotid_L_cagr 33.47 29.48 13.71 14.83 36.81 29.76 -19.76 -14.64 -7.05
parotid_R_cagr 31.55 28.91 13.70 15.17 36.94 32.38 -17.85 -13.74 -4.56
parotids 32.47 29.20 13.71 15.00 36.94 32.38 -18.77 -14.20 -4.56
pitutary 38.46 38.43 39.77 39.75 39.01 42.00 1.31 1.31 2.99
retinaLT 28.34 27.18 25.41 26.31 37.87 37.45 -2.94 -0.88 -0.42
retina Rt 28.88 26.73 25.42 26.14 37.40 36.95 -3.46 -0.58 -0.45
scalp 34.51 33.68 32.19 31.00 39.49 40.92 -2.32 -2.68 1.43
spinal cord 36.34 36.38 36.10 36.09 38.31 37.72 -0.24 -0.29 -0.58
TemporalLobeLt 39.50 39.78 41.36 41.52 54.80 54.65 1.86 1.74 -0.14
temporallobeRT 39.96 37.35 40.21 40.33 54.19 54.08 0.25 2.98 -0.11
thecalsac 36.51 36.49 36.21 36.15 37.26 37.72 -0.30 -0.34 0.46
Patient P3
OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
bladder 0.00 2.21 6.59 8.66 53.69 49.23 6.59 6.46 -4.45
bowel large 0.01 4.59 11.64 14.25 56.38 56.36 11.64 9.66 -0.03
bowel small 0.00 0.15 1.27 5.81 55.77 54.34 1.27 5.66 -1.43
fermur left 0.00 0.00 0.99 1.54 0.01 4.89 0.99 1.54 4.89
fermur right 1.07 11.64 3.67 7.63 55.78 55.91 2.60 -4.01 0.13
growth plate  0.01 1.42 2.44 2.50 23.50 6.02 2.44 1.08 -17.48
Growth plate left 0.00 0.00 1.10 1.26 0.01 3.18 1.10 1.26 3.17
growth plate right 0.99 2.81 3.68 3.72 23.46 6.02 2.69 0.91 -17.43
kidneyLt 0.00 0.00 0.01 0.09 0.01 0.64 0.00 0.09 0.64
kidney rt 0.00 0.00 0.01 0.25 0.01 1.54 0.01 0.25 1.53
non target body 0.00 3.47 0.77 5.82 58.05 57.26 0.77 2.35 -0.79
non target bowel 0.00 2.34 5.44 10.07 56.23 55.96 5.44 7.73 -0.27







OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
brain 25.00 29.73 24.25 29.14 56.74 55.60 -0.75 -0.59 -1.14
brainSupra tent 24.75 27.06 24.16 26.27 56.33 54.99 -0.60 -0.79 -1.34
brain stem 51.51 47.96 52.30 49.68 56.38 55.48 0.79 1.72 -0.90
brainstemCore 50.00 48.04 50.53 49.55 55.97 55.48 0.54 1.51 -0.49
brain stemsurface 53.12 47.95 53.97 49.86 56.39 55.46 0.85 1.91 -0.92
cerebellum 51.88 47.44 48.35 47.39 56.74 55.49 -3.53 -0.05 -1.26
cochlea LT 25.38 25.40 34.27 34.27 26.13 34.79 8.89 8.88 8.67
cochlea Rt 30.85 30.89 38.66 38.70 33.23 39.61 7.82 7.81 6.38
cribriform 24.77 24.78 24.35 24.59 25.15 27.64 -0.42 -0.19 2.49
heart 0.00 0.20 7.65 8.41 21.87 22.58 7.65 8.21 0.71
Hippo head Lt 26.30 27.49 32.10 32.32 39.18 37.84 5.80 4.83 -1.33
hippohead Rt 26.63 27.30 36.28 36.35 34.01 41.05 9.65 9.05 7.04
hippo Lt 29.76 33.41 32.81 33.59 52.40 45.30 3.05 0.18 -7.10
hippoRt 28.59 30.91 36.35 36.35 47.26 41.05 7.77 5.44 -6.21
Hippo Tail Lt 44.67 43.62 35.07 35.60 52.40 45.30 -9.60 -8.01 -7.10
hippo tai Rt 38.54 38.15 36.48 36.30 47.26 39.48 -2.07 -1.85 -7.78
hypothalamus 32.22 33.62 30.61 32.80 51.60 53.60 -1.61 -0.82 2.00
kidneyLt 0.04 2.90 6.03 7.48 23.65 23.42 5.99 4.59 -0.23
kidney rt 0.25 4.54 7.69 8.96 4.54 23.21 7.44 4.42 18.66
lacrimal Rt 23.24 22.57 17.96 18.22 23.78 22.95 -5.27 -4.35 -0.82
lensLt 16.20 16.03 14.45 14.45 18.55 15.13 -1.75 -1.59 -3.42
lensRt 12.67 12.81 13.69 13.81 19.47 15.12 1.02 1.01 -4.35
lung Lt 0.00 1.06 2.59 3.55 23.69 23.41 2.59 2.49 -0.28
lung Rt 0.00 3.09 5.22 6.28 24.03 24.08 5.22 3.19 0.05
lungs 0.00 2.30 3.68 5.21 24.03 24.08 3.68 2.91 0.05
MastoidLt 30.15 28.83 31.69 31.50 32.28 36.72 1.54 2.67 4.44
mastoidRt 30.27 29.16 33.97 33.84 33.35 40.51 3.69 4.68 7.16
non target body 0.00 3.43 3.13 6.36 54.80 53.42 3.12 2.94 -1.38
optichaism 25.08 25.08 29.74 29.73 25.12 30.53 4.66 4.65 5.41
optic nervLt 24.86 24.84 26.76 26.13 25.10 29.35 1.90 1.29 4.25
optic nerveRt 24.93 24.89 27.03 26.73 25.13 30.35 2.11 1.84 5.22
parotid_L_cagr 19.49 18.46 21.47 21.53 27.61 30.29 1.98 3.07 2.68
parotid_R_cagr 19.63 18.03 22.79 22.82 26.86 32.98 3.16 4.79 6.12
parotids 19.56 18.25 22.04 22.17 27.61 32.98 2.49 3.92 5.37
pitutary 25.08 25.07 32.81 32.78 25.25 33.75 7.74 7.71 8.50
retinaLT 21.35 20.38 17.96 18.22 24.72 24.05 -3.39 -2.16 -0.67
retina Rt 18.52 17.31 16.61 16.83 24.65 22.94 -1.91 -0.48 -1.71
scalp 22.36 22.56 20.42 20.48 31.01 33.20 -1.94 -2.09 2.19
spinal cord 23.29 23.86 23.83 24.34 47.58 48.52 0.54 0.48 0.94
TemporalLobeLt 24.71 27.57 27.67 28.70 56.11 53.28 2.97 1.13 -2.83
temporallobeRT 24.50 27.16 29.35 29.72 56.13 54.38 4.85 2.56 -1.75
thecalsac 23.66 23.65 24.24 24.24 23.73 24.49 0.58 0.59 0.76






OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
brain 24.77 28.10 24.18 27.44 56.44 57.88 -0.59 -0.67 1.43
brainSupra tent 24.61 25.96 24.12 25.23 53.88 53.76 -0.49 -0.73 -0.13
brain stem 46.78 44.10 43.99 42.59 56.15 56.40 -2.79 -1.51 0.26
brainstemCore 46.82 44.66 43.67 42.21 55.67 56.28 -3.15 -2.45 0.61
brain stemsurface 47.44 43.98 44.77 43.35 56.16 56.40 -2.67 -0.63 0.25
cerebellum 42.70 43.14 39.77 42.35 56.44 57.57 -2.93 -0.80 1.13
cochlea LT 24.68 24.69 34.61 34.59 25.23 35.37 9.92 9.90 10.14
cochlea Rt 25.68 25.74 36.53 36.58 27.24 37.91 10.86 10.83 10.67
cribriform 24.64 24.64 24.21 24.15 25.24 24.49 -0.44 -0.49 -0.75
Esophagus 9.05 10.28 20.97 20.51 23.63 23.73 11.92 10.22 0.10
heart 0.00 0.63 7.89 8.56 24.13 21.73 7.89 7.93 -2.41
Hippo head Lt 26.06 26.53 27.91 28.24 31.10 32.58 1.85 1.71 1.48
hippohead Rt 27.80 28.21 26.73 27.43 33.76 33.89 -1.07 -0.78 0.13
hippo Lt 32.82 31.65 26.51 27.10 40.60 32.58 -6.31 -4.55 -8.02
hippoRt 32.42 31.59 26.12 26.85 39.94 33.89 -6.30 -4.74 -6.05
Hippo Tail Lt 34.50 34.20 25.98 26.52 40.60 32.47 -8.52 -7.69 -8.13
hippo tai Rt 34.77 34.88 25.87 26.26 39.94 33.29 -8.90 -8.62 -6.66
hypothalamus 25.81 27.17 24.57 24.62 33.25 25.28 -1.24 -2.55 -7.98
kidneyLt 0.00 2.61 6.91 8.09 23.58 23.17 6.91 5.48 -0.41
kidney rt 0.10 4.30 9.09 9.99 23.52 23.76 8.99 5.70 0.24
lacrimal Rt 23.00 22.39 16.63 16.89 23.66 21.11 -6.37 -5.50 -2.55
lensLt 14.39 14.54 13.27 13.31 19.55 21.67 -1.12 -1.23 2.12
lensRt 17.00 16.79 13.37 13.37 19.86 14.28 -3.63 -3.42 -5.59
lung Lt 0.00 2.44 7.00 8.34 24.78 14.19 6.99 5.90 -10.59
lung Rt 0.00 4.59 7.61 8.75 25.68 23.16 7.61 4.16 -2.51
lungs 0.00 3.63 7.31 8.57 25.68 24.15 7.31 4.94 -1.53
MastoidLt 23.50 23.51 31.69 31.27 26.68 37.25 8.19 7.76 10.57
mastoidRt 23.76 24.46 32.64 32.20 32.12 39.19 8.88 7.75 7.06
non target body 0.00 3.94 5.35 7.76 52.86 48.81 5.35 3.81 -4.06
optichaism 24.91 24.91 24.67 24.66 24.97 24.78 -0.25 -0.25 -0.19
optic nervLt 24.70 24.65 24.56 23.69 24.93 24.75 -0.14 -0.95 -0.18
optic nerveRt 24.70 24.69 24.24 23.83 24.90 26.65 -0.46 -0.86 1.74
parotid_L_cagr 22.23 19.78 18.69 18.30 24.13 26.57 -3.54 -1.48 2.44
parotid_R_cagr 22.96 21.48 20.24 19.63 24.29 28.34 -2.72 -1.86 4.06
parotids 22.67 20.59 19.22 18.93 24.29 28.34 -3.46 -1.66 4.06
pitutary 24.85 24.86 25.80 26.32 24.97 30.10 0.94 1.46 5.13
retinaLT 19.19 18.34 15.64 16.01 24.44 21.66 -3.54 -2.33 -2.77
retina Rt 21.69 20.43 15.35 16.03 24.53 22.33 -6.34 -4.40 -2.19
scalp 22.58 22.97 21.27 21.40 30.65 30.77 -1.31 -1.58 0.13
spinal cord 23.43 23.72 23.97 24.02 40.28 32.37 0.54 0.30 -7.92
TemporalLobeLt 24.25 26.01 25.14 27.33 53.41 51.48 0.88 1.32 -1.94
temporallobeRT 24.25 25.79 24.79 26.73 52.67 50.28 0.54 0.94 -2.39
thecalsac 23.78 23.79 23.83 23.89 23.96 24.70 0.05 0.10 0.75








OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
bladder 0.00 0.02 0.51 0.58 3.54 2.15 0.50 0.56 -1.38
bones 21.41 20.06 21.13 17.44 23.28 22.78 -0.28 -2.61 -0.50
bowel  1.58 7.12 12.60 13.10 21.87 22.05 11.02 5.98 0.18
bowel large 0.00 2.58 8.26 8.77 21.99 21.73 8.25 6.18 -0.26
bowel small 0.24 5.62 10.50 11.28 22.34 22.10 10.27 5.66 -0.24
growthplate left 0.00 0.00 0.26 0.26 0.00 0.27 0.26 0.26 0.27
growthplateright 0.00 0.00 0.23 0.23 0.00 0.25 0.23 0.23 0.24
growthplates 0.00 0.00 0.25 0.25 0.00 0.27 0.25 0.24 0.27
kidneyLt 0.07 3.63 1.04 4.27 22.05 21.50 0.97 0.64 -0.55
kidney rt 6.15 8.71 6.11 8.65 22.01 21.58 -0.04 -0.06 -0.44
kidneys 1.25 6.03 3.39 6.33 22.05 21.58 2.14 0.31 -0.47
liver 0.00 0.04 3.58 3.65 3.78 9.41 3.58 3.61 5.63
non target body 0.00 1.40 0.18 2.15 23.39 22.40 0.17 0.76 -0.99
non target bowel 0.23 5.58 10.48 11.25 22.34 22.09 10.25 5.68 -0.25
rectum 0.06 1.12 0.33 0.39 10.93 0.90 0.28 -0.73 -10.03
skin 0.01 1.30 0.20 2.15 23.16 21.80 0.19 0.85 -1.36
spinal cord 0.00 0.01 0.30 0.35 1.32 0.77 0.30 0.34 -0.55
vertebral bodies 21.37 21.40 21.43 21.45 22.09 22.33 0.06 0.05 0.24
Patient P7
OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
bones 50.33 47.48 51.07 48.57 52.10 54.31 0.74 1.08 2.21
breast 0.00 0.00 2.23 3.70 0.00 13.42 2.22 3.70 13.42
Esophagus 37.91 31.62 43.47 36.58 50.94 53.55 5.56 4.95 2.60
heart 0.00 0.40 1.29 3.50 33.23 40.56 1.29 3.10 7.33
lung Lt 0.01 6.53 11.32 11.96 52.20 52.85 11.31 5.43 0.64
lung Rt 0.11 10.19 9.23 13.95 53.66 52.50 9.12 3.76 -1.16
lungs 0.04 8.58 10.14 13.07 53.66 52.85 10.10 4.50 -0.82
non target body 0.00 2.29 0.28 4.69 53.66 54.26 0.28 2.40 0.59
non target lung 0.04 8.56 10.13 13.06 53.66 52.85 10.09 4.50 -0.82
spainal cord 49.49 36.74 49.52 35.29 50.99 51.08 0.03 -1.45 0.10
thyroid 1.20 2.29 24.57 24.19 13.66 38.85 23.37 21.90 25.19






OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
brain 37.69 39.48 36.82 38.82 56.41 55.41 -0.87 -0.66 -1.00
brainSupra tent 37.53 38.31 36.58 37.32 55.29 54.89 -0.94 -0.99 -0.40
brain stem 50.22 48.40 52.48 51.16 54.90 55.33 2.27 2.76 0.43
brainstemCore 50.30 48.81 52.61 51.57 53.82 55.33 2.31 2.76 1.52
brain stemsurface 50.20 47.96 52.30 50.73 54.90 55.27 2.10 2.77 0.37
cerebellum 47.08 47.52 47.73 48.28 56.41 55.40 0.64 0.75 -1.01
cochlea LT 37.83 37.87 39.46 39.54 38.47 41.13 1.63 1.67 2.65
cochlea Rt 37.99 37.98 40.15 40.13 38.55 40.56 2.16 2.15 2.01
cribriform 37.08 37.08 35.90 35.94 37.76 38.93 -1.18 -1.14 1.17
Esophagus 0.00 0.49 17.99 18.44 21.55 31.26 17.99 17.95 9.71
heart 0.00 0.03 7.14 7.42 12.75 15.00 7.14 7.39 2.25
Hippo head Lt 38.49 39.04 41.71 41.80 43.85 44.84 3.22 2.76 1.00
hippohead Rt 38.34 38.73 40.86 40.91 41.67 42.34 2.52 2.19 0.67
hippo Lt 43.99 43.32 41.98 41.86 50.97 47.84 -2.02 -1.46 -3.13
hippoRt 41.73 41.19 40.84 40.51 46.58 42.66 -0.89 -0.68 -3.92
Hippo Tail Lt 46.66 46.48 42.37 41.90 50.97 47.84 -4.29 -4.58 -3.13
hippo tai Rt 42.81 42.98 40.80 40.20 46.58 42.66 -2.01 -2.78 -3.92
hypothalamus 37.94 38.99 37.49 37.71 46.40 42.51 -0.44 -1.28 -3.89
kidneyLt 0.00 0.46 9.18 10.13 31.30 29.89 9.17 9.66 -1.40
kidney rt 0.00 0.74 8.14 9.30 35.06 31.04 8.13 8.56 -4.02
lacrimal Lt 35.19 30.51 24.93 24.73 37.06 30.36 -10.26 -5.79 -6.70
lacrimal Rt 35.72 32.16 23.90 24.11 37.03 29.78 -11.82 -8.05 -7.24
lensLt 23.39 23.13 21.56 21.57 28.26 23.22 -1.83 -1.56 -5.04
lensRt 21.53 20.99 20.64 20.17 27.95 21.83 -0.89 -0.83 -6.12
lung Lt 0.00 1.59 7.21 8.75 39.58 37.43 7.20 7.17 -2.16
lung Rt 0.00 2.18 8.31 9.90 40.84 36.89 8.30 7.73 -3.95
Lungs 0.03 1.89 7.77 9.35 40.84 37.43 7.74 7.46 -3.41
MastoidLt 38.08 38.27 37.92 37.54 41.22 45.01 -0.17 -0.73 3.78
mastoidRt 37.10 37.17 34.48 33.95 40.89 42.72 -2.62 -3.22 1.83
non target body 0.00 4.27 4.83 7.84 56.22 55.35 4.83 3.57 -0.87
non target brain 37.66 39.11 36.77 38.46 56.22 55.35 -0.89 -0.65 -0.86
optichaism 37.74 37.74 40.88 40.86 37.86 41.94 3.14 3.12 4.08
optic nervLt 37.21 37.19 35.09 35.03 38.22 40.91 -2.11 -2.16 2.69
optic nerveRt 37.40 37.39 35.00 34.76 38.73 40.82 -2.40 -2.64 2.10
parotid_L_cagr 27.66 26.86 15.89 16.29 38.24 26.88 -11.77 -10.57 -11.36
parotid_R_cagr 31.51 28.32 16.42 16.50 37.67 28.53 -15.09 -11.82 -9.13
parotids 29.62 27.56 16.09 16.39 38.24 28.53 -13.54 -11.17 -9.70
pitutary 37.90 37.89 40.42 40.43 38.30 41.59 2.51 2.54 3.29
retinaLT 28.70 27.12 23.73 23.73 37.32 29.88 -4.98 -3.39 -7.44
retina Rt 29.27 28.05 23.06 23.31 37.48 31.35 -6.21 -4.74 -6.13
scalp 34.25 33.38 16.84 16.45 39.50 28.64 -17.41 -16.93 -10.86
spinal cord 39.56 38.66 39.60 38.64 49.41 52.52 0.04 -0.02 3.11
TemporalLobeLt 38.03 38.88 38.83 39.24 54.58 54.47 0.80 0.36 -0.10
temporallobeRT 38.01 38.63 39.22 39.03 50.81 48.92 1.22 0.40 -1.88
thecalsac 36.48 36.53 36.45 36.44 37.46 37.31 -0.03 -0.09 -0.15








OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
brain 23.60 30.78 24.95 32.64 56.92 55.84 1.35 1.85 -1.08
brainSupra tent 23.51 26.87 24.54 29.03 55.61 55.66 1.03 2.16 0.05
brain stem 53.42 53.23 53.22 52.92 54.40 54.32 -0.20 -0.31 -0.08
chiasma 34.70 35.07 37.65 38.48 50.65 50.62 2.95 3.41 -0.03
cochlea LT 28.47 28.64 42.02 42.17 33.63 47.30 13.55 13.53 13.67
cochlea Rt 29.24 29.56 42.66 42.85 35.63 46.98 13.43 13.30 11.35
cord 23.42 23.87 23.57 24.03 50.73 52.20 0.15 0.16 1.47
eye left 2.20 3.97 10.13 13.12 18.92 26.07 7.93 9.15 7.15
eye right 1.33 2.99 19.22 16.78 17.42 26.41 17.88 13.79 8.99
heart 0.00 0.23 7.72 8.08 8.07 19.35 7.72 7.85 11.28
hippo Lt 48.55 47.51 50.16 49.13 55.33 54.70 1.62 1.62 -0.63
hippoRt 49.78 48.50 50.06 49.92 55.33 54.86 0.28 1.42 -0.47
hypothalamus 39.45 39.75 31.90 33.12 51.30 49.18 -7.55 -6.63 -2.12
inner ear left 31.34 32.48 43.05 43.38 47.33 53.40 11.72 10.90 6.07
inner ear right 31.94 32.84 43.16 43.73 46.66 54.45 11.21 10.89 7.79
kidneyLt 0.00 0.37 1.95 3.12 17.48 21.41 1.94 2.75 3.93
kidney rt 0.00 0.48 2.21 3.89 18.87 22.56 2.21 3.41 3.69
lensLt 0.94 1.01 4.73 4.89 2.13 8.16 3.78 3.88 6.03
lensRt 0.67 0.75 5.84 5.97 1.93 10.81 5.18 5.22 8.87
lung Lt 0.00 1.21 2.44 3.87 21.80 22.62 2.43 2.66 0.82
lung Rt 0.01 1.48 4.03 5.58 23.14 23.40 4.02 4.09 0.25
Lungs 0.00 1.21 3.17 4.82 21.78 23.40 3.16 3.61 1.62
optichaism 28.15 28.35 33.33 33.43 32.15 37.88 5.17 5.08 5.73
optic nervLt 21.89 18.79 26.42 25.11 27.38 34.91 4.53 6.32 7.52
optic nerveRt 22.14 18.10 27.13 27.59 26.64 37.35 4.99 9.48 10.71
parotid_L_cagr 1.88 3.06 22.69 23.03 19.50 42.08 20.81 19.97 22.59
parotid_R_cagr 2.43 4.08 24.20 23.44 20.13 40.67 21.77 19.36 20.54
parotids 2.13 3.55 23.67 23.23 20.13 42.08 21.55 19.68 21.95
pitutary 32.96 33.26 39.36 39.61 41.68 45.74 6.40 6.35 4.07
skin 0.00 2.72 0.89 5.41 56.92 55.91 0.88 2.69 -1.02
spinalkanal 23.43 24.65 23.56 24.70 54.75 54.70 0.13 0.05 -0.05
TMJ left 20.01 19.66 36.85 35.95 24.38 38.42 16.85 16.29 14.04
TMJ right 20.48 20.05 40.87 41.03 26.36 44.75 20.40 20.98 18.39
Testicles 0.00 0.00 0.03 0.56 0.00 0.16 0.03 0.56 0.15
Thyroid 0.00 0.00 17.20 17.50 0.76 22.52 17.19 17.50 21.76
TemporalLobeLt 23.93 28.39 37.69 37.03 55.40 55.15 13.76 8.65 -0.25
temporallobeRT 24.15 28.99 37.32 36.18 54.98 55.45 13.17 7.19 0.46
Patient P10
OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
bowel large 0.00 0.45 0.65 3.79 22.80 23.48 0.64 3.34 0.68
bowel small 0.03 4.10 1.12 6.42 23.10 23.49 1.09 2.32 0.39
heart 0.00 0.28 1.07 4.87 17.70 23.34 1.06 4.59 5.64
kidneyLt 8.74 9.79 1.24 2.38 22.95 21.42 -7.50 -7.41 -1.53
kidneyRt 19.67 16.75 23.18 22.78 23.38 23.77 3.51 6.03 0.39
liver 2.94 6.06 3.87 10.60 24.11 23.63 0.93 4.54 -0.48
lung Lt 0.00 0.20 0.35 0.47 20.31 15.72 0.35 0.27 -4.59
lung Rt 0.00 2.13 0.65 2.11 24.37 23.46 0.65 -0.02 -0.91
lungs 0.00 1.36 0.51 1.46 24.37 23.46 0.50 0.10 -0.91
non target body 0.00 2.22 0.51 3.58 23.96 24.08 0.51 1.37 0.12
non target bowel 0.00 1.51 0.79 4.45 22.91 23.49 0.79 2.93 0.57
non target lung 0.00 1.14 0.50 1.24 24.10 23.46 0.50 0.11 -0.65
spinal cord 0.00 1.14 17.88 11.81 22.55 22.59 17.88 10.68 0.04
stomach 0.01 3.26 1.92 6.72 23.15 22.76 1.92 3.46 -0.38






OAR Prmed Prmea Phmed Phmea Prmax Phmax Phmed-Prmed Phmea-phmea Phmax-Prmax
Esophagus 19.01 15.79 18.18 15.47 22.32 21.25 -0.83 -0.32 -1.08
heart 0.00 0.75 8.82 9.19 21.36 21.08 8.82 8.44 -0.28
liver 0.00 0.00 0.18 0.24 0.46 3.22 0.18 0.24 2.76
lung Lt 2.49 8.32 13.24 12.25 23.03 21.96 10.75 3.93 -1.07
lung Rt 0.00 1.16 4.24 3.94 20.85 20.06 4.24 2.78 -0.79
lungs 0.00 3.99 4.81 7.23 23.03 21.96 4.80 3.23 -1.07
non target body 0.00 1.45 0.26 2.57 22.84 22.06 0.26 1.13 -0.77
non target lung 0.00 3.94 4.80 7.18 23.03 21.96 4.79 3.24 -1.07
skin 0.00 0.98 0.21 1.87 22.09 21.11 0.21 0.89 -0.99
spinal cord 10.69 10.73 3.17 10.11 22.03 21.89 -7.52 -0.63 -0.13
stomach 0.00 0.00 0.46 0.50 0.56 1.17 0.46 0.49 0.61
Patient P12
